Dementia biomarkers are crucial indicators used in Alzheimer's disease and other forms of dementia to diagnose, track progression, and assess response to treatment. These biomarkers include proteins like beta-amyloid and tau in cerebrospinal fluid or through imaging techniques like PET scans. Genetic markers such as the APOE ε4 allele also play a significant role. Biomarkers aid in early detection before symptoms manifest, enabling timely interventions. Research focuses on identifying novel biomarkers to enhance diagnostic accuracy and therapeutic targeting, aiming to improve patient outcomes and facilitate the development of disease-modifying treatments. Integrating biomarker findings with clinical assessments enhances diagnostic precision and supports personalized care approaches in managing Alzheimer’s and related dementias.
Jun Hua
Johns Hopkins University , United States
Nazneen N Dewji
Cenna Biosciences Inc, United States
Jacqueline London
Paris Diderot University, FranceSubmit your abstract Today
Title : Neuroimaging-based evaluation of scalp acupuncture for neural repair and reorganization in children with cerebral palsy
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Neuromodulation of scalp electroacupuncture in the treatment of autism spectrum disorder
Zhenhuan Liu, Guangzhou University of Chinese Medicine, China
Title : Make a difference
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Association between depressive symptoms and cognitive impairment severity in a real-world memory clinic cohort
Yun Ju Hsieh, Taipei City Hospital, Taiwan
Title : Health care professionals in Somaliland had low levels of knowledge and attitudes towards dementia care: A pilot survey
Mohamed Abdilahi Duale, Somali Red Crescent Society, Somalia
Title : Imaging brain clearance in Alzheimer’s disease
Jun Hua, Johns Hopkins University , United States